Medscape

Pyoderma Gangrenosum in Pregnancy Often Misdiagnosed

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
Healio

Beneath the Surface: ‘Optimism is high’ for complex wound disease treatments

Please provide your email address to receive an email when new articles are posted on . There are few medications dermatologists can prescribe for pyoderma gangrenosum, a complex wound disease.
Nasdaq

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Nasdaq

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...
Seeking Alpha

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral ...